Blood purification with CytoSorb in critically ill COVID‐19 patients: A case series of 26 patients
Open Access
- 6 July 2021
- journal article
- research article
- Published by Wiley in Artificial Organs
- Vol. 45 (11) , 1338-1347
Abstract
Severe forms of the coronavirus disease 2019 (COVID‐19) can progress to sepsis‐like complications accompanied by “cytokine storm” for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID‐19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID‐19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre‐, and post‐treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C‐reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO2/FiO2 and overall organ function (ie, Sequential Organ Failure Assessment—SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS‐CoV‐2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well‐tolerated.Keywords
This publication has 28 references indexed in Scilit:
- Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center studyJournal of Artificial Organs, 2017
- Hemoadsorption by CytoSorb in septic patients: a case seriesCritical Care, 2017
- Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat modelCritical Care, 2014
- Control of Core Temperature and Blood Pressure Stability during HemodialysisClinical Journal of the American Society of Nephrology, 2009
- Effects of hemoadsorption on cytokine removal and short-term survival in septic ratsCritical Care Medicine, 2008
- Understanding the Inflammatory Cytokine Response in Pneumonia and SepsisArchives of internal medicine (1960), 2007
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Interpreting the Mechanisms of Continuous Renal Replacement Therapy in Sepsis: The Peak Concentration HypothesisArtificial Organs, 2003
- Such stuff as dreams are made on: mediator-directed therapy in sepsisNature Reviews Drug Discovery, 2003
- Cytokine Therapeutics for the Treatment of Sepsis: Why has Nothing Worked?Current Pharmaceutical Design, 2003